Moderna shares tumbled more than 10% premarket after the company lowered its sales outlook amid an increasingly competitive environment in the U.S. and very low sales in Europe.
Moderna shares tumbled more than 10% premarket after the company lowered its sales outlook amid an increasingly competitive environment in the U.S. and very low sales in Europe.